{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T22:21:25Z","timestamp":1788128485209,"version":"build-2803163510"},"reference-count":39,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001430"],"award-info":[{"award-number":["UL1TR001430"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30AI042853"],"award-info":[{"award-number":["P30AI042853"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI119037"],"award-info":[{"award-number":["R01AI119037"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI111276"],"award-info":[{"award-number":["U19AI111276"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U01AA020784"],"award-info":[{"award-number":["U01AA020784"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U24AA020778"],"award-info":[{"award-number":["U24AA020778"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["U24AA020779"],"award-info":[{"award-number":["U24AA020779"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To quantify the proportion of people living with HIV (PLWH) with other tuberculosis (TB) risk factors that completed the latent tuberculosis infection (LTBI) care cascade and describe factors associated with attrition. The care cascade was defined as follows: (1) receipt of an LTBI test and result, (2) initiation of LTBI treatment and (3) completion of LTBI treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Prospective cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Reactivation of LTBI remains a large source of active TB disease in the USA. PLWH and those who use substances are at greater risk and are harder to engage and retain in care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Participants enrolled in a Boston cohort of PLWH from 2012 to 2014.<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>Our primary outcome was the number and proportion of participants who completed each stage of the cascade and the factors associated with completing each stage. Our secondary outcomes were differences between participants tested with an interferon gamma release assay (IGRA) versus tuberculin skin test and differences between participants who tested positive versus negative for LTBI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Only 189 of 219 (86.3%) participants completed testing. Five of the 11 with LTBI initiated and three completed treatment. Participants tested with an IGRA were more likely to complete testing (OR 3.87, 95% CI 1.05 to 14.30) while among participants successfully tested, being foreign-born was associated with a positive test result (OR 3.95; 95% CI 1.13 to 13.77).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although the majority completed LTBI testing, our findings warrant further investigation in a larger cohort to better understand factors that lead to suboptimal treatment initiation and completion in a low-burden country.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2021-058751","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T16:57:26Z","timestamp":1646931446000},"page":"e058751","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Testing and treatment for latent tuberculosis infection in people living with HIV and substance dependence: a prospective cohort study"],"prefix":"10.1136","volume":"12","author":[{"given":"Tessa","family":"Runels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6062-0058","authenticated-orcid":false,"given":"Elizabeth J","family":"Ragan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia S","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Robert","family":"Horsburgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H","family":"Samet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Saitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"2023030803132088000_12.3.e058751.1"},{"key":"2023030803132088000_12.3.e058751.2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw778"},{"key":"2023030803132088000_12.3.e058751.3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000171.pub3"},{"key":"2023030803132088000_12.3.e058751.4","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00042-10"},{"key":"2023030803132088000_12.3.e058751.5","doi-asserted-by":"publisher","DOI":"10.1086\/594126"},{"key":"2023030803132088000_12.3.e058751.6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-8-289"},{"key":"2023030803132088000_12.3.e058751.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507198"},{"key":"2023030803132088000_12.3.e058751.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142290"},{"key":"2023030803132088000_12.3.e058751.9","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","article-title":"Effect of isoniazid preventive therapy on risk of death in West African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial","volume":"5","author":"Badje","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2023030803132088000_12.3.e058751.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30216-X"},{"key":"2023030803132088000_12.3.e058751.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003703","article-title":"The latent tuberculosis cascade-of-care among people living with HIV: a systematic review and meta-analysis","volume":"18","author":"Bastos","year":"2021","journal-title":"PLoS Med"},{"key":"2023030803132088000_12.3.e058751.12","article-title":"Low adherence to guidelines for preventing TB among persons with newly diagnosed HIV infection, United States","volume":"10","author":"Lee","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023030803132088000_12.3.e058751.13","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.234"},{"key":"2023030803132088000_12.3.e058751.14","doi-asserted-by":"publisher","DOI":"10.1086\/314037"},{"key":"2023030803132088000_12.3.e058751.15","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0394"},{"key":"2023030803132088000_12.3.e058751.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200303-390OC"},{"key":"2023030803132088000_12.3.e058751.17","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023030803132088000_12.3.e058751.18","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.11.0814"},{"key":"2023030803132088000_12.3.e058751.19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw126"},{"key":"2023030803132088000_12.3.e058751.20","first-page":"775","article-title":"A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection","volume":"10","author":"Nyamathi","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023030803132088000_12.3.e058751.21","doi-asserted-by":"crossref","first-page":"961","DOI":"10.5588\/ijtld.15.0988","article-title":"Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California","volume":"20","author":"Shin","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023030803132088000_12.3.e058751.22","first-page":"1104","article-title":"Predictors of latent tuberculosis infection treatment completion in the United States: an inner City experience","volume":"14","author":"Hirsch-Moverman","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023030803132088000_12.3.e058751.23","first-page":"160","article-title":"Successful use of rifampicin for Hispanic foreign-born patients with latent tuberculosis infection","volume":"12","author":"Haley","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"2023030803132088000_12.3.e058751.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-018-5393-x","article-title":"Care cascade for targeted tuberculosis testing and linkage to care in homeless populations in the United States: a meta-analysis","volume":"18","author":"Parriott","year":"2018","journal-title":"BMC Public Health"},{"key":"2023030803132088000_12.3.e058751.25","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006759","article-title":"Lifetime and recent alcohol use and bone mineral density in adults with HIV infection and substance dependence","volume":"96","author":"Ventura","year":"2017","journal-title":"Medicine"},{"key":"2023030803132088000_12.3.e058751.26","unstructured":"U.S. Department of Health and Human Services . Tuberculin skin testing [online], 2020. Available: https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/testing\/skintesting.pdf [Accessed 12 Jan 2022]."},{"key":"2023030803132088000_12.3.e058751.27","unstructured":"Qiagen . FAQs for health professionals: quantiFERON-TB gold [online], 2016. Available: https:\/\/www.quantiferon.com\/wp-content\/uploads\/2017\/05\/PROM-10157_FAQs-Health-Professionals-Rev001v02.pdf [Accessed 12 Jan 2022]."},{"key":"2023030803132088000_12.3.e058751.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101313","article-title":"Opportunities for tuberculosis diagnosis and prevention among persons living with HIV: a cross-sectional study of policies and practices at four large Ryan White Program-funded HIV clinics","volume":"9","author":"Pascopella","year":"2014","journal-title":"PLoS One"},{"key":"2023030803132088000_12.3.e058751.29","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1080\/09540121.2017.1325438","article-title":"Tuberculosis screening among HIV-infected patients: tuberculin skin test vs. interferon-gamma release assay","volume":"29","author":"Adams","year":"2017","journal-title":"AIDS Care"},{"key":"2023030803132088000_12.3.e058751.30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3201\/eid2103.141475","article-title":"Characteristics of tuberculosis cases that started outbreaks in the United States, 2002-2011","volume":"21","author":"Haddad","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2023030803132088000_12.3.e058751.31","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.5588\/ijtld.17.0041","article-title":"Latent tuberculous infection testing among HIV-infected persons in clinical care, United States, 2010\u20132012","volume":"21","author":"Reaves","year":"2017","journal-title":"int j tuberc lung dis"},{"key":"2023030803132088000_12.3.e058751.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201508-1683OC"},{"key":"2023030803132088000_12.3.e058751.33","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-5-200703060-00006"},{"key":"2023030803132088000_12.3.e058751.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243102","article-title":"Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: evidence from commercial insurance data","volume":"15","author":"Stockbridge","year":"2020","journal-title":"PLoS One"},{"key":"2023030803132088000_12.3.e058751.35","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001098"},{"key":"2023030803132088000_12.3.e058751.36","unstructured":"Swindells S , Ramchandani R , Gupta A . One month of rifapentine\/isoniazid to prevent TB in people with HIV: brief-TB\/A5279. In: conference on retroviruses and opportunistic infections. Boston, 2018."},{"key":"2023030803132088000_12.3.e058751.37","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/rccm.201912-2489OC","article-title":"Rifapentine population pharmacokinetics and dosing recommendations for latent tuberculosis infection","volume":"202","author":"Hibma","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2023030803132088000_12.3.e058751.38","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1549-4"},{"key":"2023030803132088000_12.3.e058751.39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5588\/ijtld.19.0185","article-title":"Interventions to reduce losses in the cascade of care for latent tuberculosis: a systematic review and meta-analysis","volume":"24","author":"Barss","year":"2020","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-058751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T12:04:01Z","timestamp":1678277041000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-058751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,28]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/bmjopen-2021-058751"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-058751","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}